Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)

References

• Canellos GP, Rosenberg SA, Friedberg JW, et al. Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014;32:163–168.
   PubMed Web of Science ®Google Scholar
• Sjoberg J, Halthur C, Kristinsson SY, et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood. 2012;119:990–996.
   PubMed Web of Science ®Google Scholar
• Diepstra A, van Imhoff GW, Schaapveld M, et al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. Jco. 2009;27:3815–3821.
   PubMed Web of Science ®Google Scholar
• Levis A, Anselmo AP, Ambrosetti A, et al. VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol. 2004;15:123–128.
   PubMed Web of Science ®Google Scholar
• Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. Jco. 2005;23:5052–5060.
   PubMedGoogle Scholar
• Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. Jco. 2001;19:1444–1454.
   PubMed Web of Science ®Google Scholar
• Luminari S, Montanini A, Caballero D, et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol. 2010;21:1492–1499.
   PubMed Web of Science ®Google Scholar
• Dell'Olio M, Scalzulli RP, Sanpaolo G, et al. Non-pegylated liposomal doxorubicin (Myocet(R)) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2011;52:1222–1229.
   PubMed Web of Science ®Google Scholar
• Luminari S, Viel E, Ferreri AJM, et al. Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. Hematol Oncol. 2018;36:68–75.
   PubMed Web of Science ®Google Scholar
• Miller MD. A manual of guidelines for scoring the cumulative illness rating scale for geriatricians (CIRS-G). Pittsburg: University of Pittsburg; 1991. p. 1–12.
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol. 1987;14:65–74.
   PubMed Web of Science ®Google Scholar
• Halbsguth TV, Boll B, Borchmann P, et al. The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma. Curr Hematol Malig Rep. 2011;6:164–171.
   PubMed Web of Science ®Google Scholar
• Zallio F, Tamiazzo S, Monagheddu C, et al. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). Br J Haematol. 2016;172:879–888.
   PubMed Web of Science ®Google Scholar
• Boll B, Gorgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. Jco. 2013;31:1522–1529.
   PubMed Web of Science ®Google Scholar
• Boll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127:2189–2192.
   PubMed Web of Science ®Google Scholar
• Proctor SJ, Wilkinson J, Jones G, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 2012;119:6005–6015.
   PubMed Web of Science ®Google Scholar
• Weekes CD, Vose JM, Lynch JC, et al. Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol. 2002;20:1087–1093.
   PubMed Web of Science ®Google Scholar
• Landgren O, Algernon C, Axdorph U, et al. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica. 2003;88:438–444.
   PubMed Web of Science ®Google Scholar
• Kanter PM, Bullard GA, Ginsberg RA, et al. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In Vivo. 1993;7:17–26.
   PubMedGoogle Scholar
• Wouters KA, Kremer LC, Miller TL, et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131:561–578.
   PubMed Web of Science ®Google Scholar
• Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94:25–36.
   PubMed Web of Science ®Google Scholar
• Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005;16:124–131.
   PubMed Web of Science ®Google Scholar
• Boll B, Bredenfeld H, Gorgen H, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. 2011;118:6292–6298.
   PubMed Web of Science ®Google Scholar
• Halbsguth TV, Nogova L, Mueller H, et al. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2010;116:2026–2032.
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126:2798–2804.
   PubMed Web of Science ®Google Scholar
• Kumar A, Casulo C, Yahalom J, et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016;128:1458–1464.
   PubMed Web of Science ®Google Scholar
• Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14:1348–1356.
   PubMed Web of Science ®Google Scholar
• Connors JM, Jurczak W, Straus DJ, et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2018;378:331–344.
   PubMed Web of Science ®Google Scholar
• A, Fosså B, Böll H, Goergen, et al. B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso (lo) ne) in older patients with advanced-stage hodgkin lymphoma: results of a phase ii intergroup trial by the german hodgkin study group (ghsg) and the nordic lymphoma group (nlg). Abstract T021 (0147). 11th International Symposium on Hodgkin Lymphoma; October 27–29; 2018.
   Google Scholar
• Evens AM, Advani RH, Helenowski IB, et al. Multicenter phase ii study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol. 2018;36:3015–3022.
   PubMedGoogle Scholar